Table 5. Patients with Reported Prolactin-Related AEs at End Point According to Gender.

	RLAI (n=329)		Quetiapine (n=337)
	Female (n=134)	Male (n=195)	Female (n=146)	Male (n=191)
Potentially prolactin-related, n (%)	10 (7.5)	5 (2.6)	5 (3.4)	0
Hyperprolactinemia, n (%)	27 (20.1)	16 (8.2)	4 (2.7)	1 (0.5)
	(n=107)	(n=145)	(n=104)	(n=133)
Mean±SD prolactin levels (mIU/l)	1590.5±924.57	767.4±540.68	855.1±1066.92	367.0±352.51

Abbreviations: AE, adverse event; RLAI, risperidone long-acting injectable.

Bold values: analysis not designed to test for differences.